{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:01Z","timestamp":1791999481439,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100016945","name":"Sidney Kimmel Center for Prostate and Urologic Cancers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016945","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health National Cancer Institute"},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016945","name":"Sidney Kimmel Center for Prostate and Urologic Cancers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Penile curvature is the most common abnormality that is observed by men with Peyronie's disease (PD). Collagenase Clostridium histolyticum (CCH) has become a standard treatment for PD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To identify predictor factors associated with improvements of penile curvature outcomes in men with PD treated with CCH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively collected the data of patients with PD treated with CCH up to 8 injections divided into 4 cycles between January 2014 and July 2020. Per protocol, penile curvature was assessed at baseline, and after the second and ford CCH cycle. If after cycle 2, curvature demonstrated no improvement, or penile curvature was significantly improved and the patient was happy, no further treatment was recommended. However, if penile curvature was significantly improved and the patient remained dissatisfied, 4 cycles were completed. Three categories of response were evaluated: improvement (\u226510 degrees or \u226520%, either 1 happens), unchanged (\u00b110 degrees or \u00b120%) or worsened (\u226510 degrees or \u226520%, either 1 happens). Logistic regression analyses were performed to evaluate predictive factors associated with penile curvature improvements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Degrees of the curvature changes between the baseline and after the cycles of CCH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 114 patients underwent CCH treatment. Median age was 57 years. Median PD duration was 11 months. At baseline, mean curvature was 47 degrees, 65% had dorsal curvature, 53% mid-shaft location, and 15% calcification. After CCH treatment, the mean final curvature was 40 degrees. A total of 44% improved the curvature, 39% had no change while 17% worsened after CCH treatment. Of men who had penile curvature improvement with CCH treatment, the mean curvature decreasing in degrees and percentage were 22 degrees and 41%, respectively. Men with baseline curvature \u2264 30, 31\u201359, and \u2265 60 degrees, the percentage curvature improvement were 29%, 43%, and 60%, respectively. Baseline curvature was the only significant predictor of penile curvature improvement after CCH (OR 1.33, 95% CI\u00a0=\u00a01.1, 1.7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Implications<\/jats:title>\n                    <jats:p>We confirmed baseline penile curvature is the most important predictive factor, and this is the first report describing proportions of penile curvature improvement with CCH treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Strengths and Limitations<\/jats:title>\n                    <jats:p>This study has several strengths, including the use of validated instruments. Nonetheless, there are limitations: the retrospective nature of the study, a single institution; and modelling device was not controlled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Penile curvature improvement was significantly more common in patients with greater baseline curvature, reaching up to 60% for patients with \u2265 60 degrees.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.jsxm.2022.08.001","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T16:51:06Z","timestamp":1663433466000},"page":"1680-1686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Predictors of Curvature Improvement in Men with Peyronie's Disease Treated with Intralesional Collagenase Clostridium Histolyticum"],"prefix":"10.1093","volume":"19","author":[{"given":"Jose M.","family":"Flores","sequence":"first","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine ProgramUrology ServiceMemorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Punjani","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A.","family":"Salter","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L.","family":"Bernie","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Miranda","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Etienne","family":"Terrier","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Schofield","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Mulhall","sequence":"additional","affiliation":[{"name":"Sexual & Reproductive Medicine Program Urology Service Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/j.1743-6109.2008.00949.x","article-title":"Risk factors for emotional and relationship problems in Peyronie's disease","volume":"5","author":"Smith","year":"2008","journal-title":"J Sex Med"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urology.2017.05.029","article-title":"Factors associated with erectile dysfunction and the Peyronie's disease questionnaire in patients with peyronie disease","volume":"107","author":"Serefoglu","year":"2017","journal-title":"Urology"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on Peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"J Sex Med"},{"key":"2023041407233346600_","first-page":"S55","article-title":"The clinical and psychosocial impact of Peyronie's disease","volume":"19","author":"Levine","year":"2013","journal-title":"Am J Manag Care"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ijir.2012.48","article-title":"How curved is too curved? The severity of penile deformity may predict sexual disability among men with Peyronie's disease","volume":"25","author":"Walsh","year":"2013","journal-title":"Int J Impot Res"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/JU.0000000000000743","article-title":"Long-term safety and curvature deformity characterization in patients previously treated with collagenase clostridium histolyticum for Peyronie's disease","volume":"203","author":"Goldstein","year":"2020","journal-title":"J Urol"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/iju.14230","article-title":"Peyronie's disease: Contemporary evaluation and management","volume":"27","author":"Ziegelmann","year":"2020","journal-title":"Int J Urol"},{"key":"2023041407233346600_","first-page":"1","article-title":"AUA Guideline Peyronie's","author":"Nehra","year":"2015","journal-title":"AUA clin Guidel"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2021.06.007","article-title":"European Association of urology guidelines on sexual and reproductive health-2021 update: Male sexual dysfunction","volume":"80","author":"Salonia","year":"2021","journal-title":"Eur Urol"},{"key":"2023041407233346600_","article-title":"Treatment of peyronie's disease with combination of clostridium histolyticum collagenase and penile traction therapy: A prospective, multicenter, single-arm study","author":"Garcia-Gomez","year":"2020","journal-title":"Int J Impot Res"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","article-title":"Efficacy of combined collagenase clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie's disease","volume":"16","author":"Alom","year":"2019","journal-title":"J Sex Med"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jsxm.2018.03.084","article-title":"Predictive factors of Patients' and their Partners' sexual function improvement after collagenase clostridium histolyticum injection for Peyronie's disease: Results from a multi-center single-arm study","volume":"15","author":"Cocci","year":"2018","journal-title":"J Sex Med"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie's disease and injectable collagenase clostridium histolyticum: Safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bju.14410","article-title":"Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease: Development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study","volume":"122","author":"Cocci","year":"2018","journal-title":"BJU Int"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: An important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie's disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00345-019-02850-3","article-title":"Characteristics predictive of response to collagenase clostridium histolyticum for Peyronie's disease: A review of the literature","volume":"38","author":"Masterson","year":"2020","journal-title":"World J Urol"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/JU.0000000000000032","article-title":"Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with Peyronie's disease: Results of a multi-institutional analysis","volume":"201","author":"Hellstrom","year":"2019","journal-title":"J Urol"},{"key":"2023041407233346600_","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","article-title":"Impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with Peyronie's disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"Urology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609522015739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609522015739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/19\/11\/1680\/49877957\/jsm_19_11_1680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/19\/11\/1680\/49877957\/jsm_19_11_1680.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T22:58:44Z","timestamp":1701039524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/19\/11\/1680\/7012871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,17]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2022.08.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742330417.793595873","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of Curvature Improvement in Men With Peyronie's Disease Treated With Intralesional Collagenase Clostridium Histolyticum","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2022.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}